Please assess the completion status of the following clinical trial:

Trial Title: Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of any solid tumor~* Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.~* At least 1 evaluable lesion per RECIST criteria~Exclusion Criteria:~* Clinically unstable primary or metastatic CNS tumors~* Subjects with known diabetes~* QTc interval greater than 470 ms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PF-05212384 (also known as PKI-587)

Based on this trial design, predict the completion outcome and termination type (if applicable).